Evidence-based medicine in times of crisis

Journal of Clinical Epidemiology

Volumn 126, Issue , 2020, Pages 164-166

  Djulbegovic, Benjamin ^a   Guyatt, Gordon ^b  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIBODY; ANTIMALARIAL AGENT; ANTIVIRUS AGENT; HYDROXYCHLOROQUINE;

CORONAVIRUS DISEASE 2019; CRITICAL ILLNESS; EDITORIAL; EVIDENCE BASED MEDICINE; GOVERNMENT; HUMAN; MEDICAL DECISION MAKING; PANDEMIC; PHYSICIAN; PRIORITY JOURNAL; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; SPANISH INFLUENZA; CRISIS INTERVENTION; DECISION MAKING; DIAGNOSIS; EPIDEMIOLOGY; GENETICS; ISOLATION AND PURIFICATION; LEGISLATION AND JURISPRUDENCE; PREVENTION AND CONTROL; PROCEDURES; PUBLIC HEALTH SERVICE; PUBLIC POLICY; VIROLOGY;

COVID-19; CRISIS INTERVENTION; DECISION MAKING; EVIDENCE-BASED MEDICINE; HUMANS; PUBLIC HEALTH ADMINISTRATION; PUBLIC POLICY; SARS-COV-2;

EID: 85088932728     PISSN: 08954356     EISSN: 18785921     Source Type: Journal    
DOI: 10.1016/j.jclinepi.2020.07.002     Document Type: Editorial

References (12)

1. Djulbegovic, B., Hozo, I., When should potentially false research findings Be considered acceptable?. PLoS Med, 4(2), 2007, e26.
2. Hozo, I., Schell, M.J., Djulbegovic, B., Decision-making when data and inferences are not conclusive: risk-benefit and acceptable regret approach. Semin Hematol 45:3 (2008), 150–159.
3. Djulbegovic, B., Guyatt, G., EBM and the theory of knowledge. Guyatt, G., Meade, M., Cook, D., (eds.) Users' Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice, 2014, McGraw-Hill, Boston.
4. Djulbegovic, B., Guyatt, G.H., Progress in evidence-based medicine: a quarter century on. Lancet 390 (2017), 415–423.
5. Guyatt, G.H., Oxman, A.D., Vist, G.E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336 (2008), 924–926.
6. Kim, A.H.J., Sparks, J.A., Liew, J.W., Putman, M.S., Berenbaum, F., Duarte-García, A., et al. A rush to judgment? Rapid reporting and dissemination of results and its consequences regarding the use of hydroxychloroquine for COVID-19. Ann Intern Med, 2020.
7. Freedman, L.P., Cockburn, I.M., Simcoe, T.S., The economics of reproducibility in preclinical research. PLoS Biol, 13(6), 2015, e1002165.
8. Available at https://www.sciencemag.org/news/2020/06/three-big-studies-dim-hopes-hydroxychloroquine-can-treat-or-prevent-covid-19. (Accessed 28 June 2020)
9. Djulbegovic, B., Paul, A., From efficacy to effectiveness in the face of uncertainty indication creep and prevention creep. JAMA 305 (2011), 2005–2006.
10. Alonso-Coello, P., Schunemann, H.J., Moberg, J., Brignardello-Petersen, R., Akl, E.A., Davoli, M., et al. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction. BMJ, 353, 2016, i2016.
11. Djulbegovic, B., Elqayam, S., Many faces of rationality: implications of the great rationality debate for clinical decision-making. J Eval Clin Pract 23 (2017), 915–922.
12. Djulbegovic, B., Elqayam, S., Dale, W., Rational decision making in medicine: implications for overuse and underuse. J Eval Clin Pract 24 (2018), 655–665.